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Abstract 
Background: The Needs Assessment Tool: Progressive Disease‑Heart Failure (NAT: PD‑HF) is a tool created to assess 
the needs of people living with heart failure and their informal caregivers to assist delivering care in a more compre‑
hensive way that addresses actual needs that are unmet, and to improve quality of life. In this study, we aimed to (1) 
Translate the tool into German and culturally adapt it. (2) Assess internal consistency, inter‑rater reliability, and test–
retest reliability of the German NAT: PD‑HF. (3) Evaluate whether and how patients and health care personnel under‑
stand the tool and its utility. (4) Assess the tool’s face validity, applicability, relevance, and acceptability among health 
care personnel.
Methods: Single‑center validation study. The tool was translated from English into German using a forward–back‑
ward translation. To assess internal consistency, we used Cronbach´s alpha. To assess inter‑rater reliability and test–
retest reliability, we used Cohen´s kappa, and to assess validity we used face validity.
Results: The translated tool showed good internal consistency. Raters were in substantial agreement on a majority 
of the questions, and agreement was almost perfect for all the questions in the test–retest analysis. Face validity was 
rated high by health care personnel.
Conclusion: The German NAT: PD‑HF is a reliable, valid, and internally consistent tool that is well accepted by both 
patients and health care personnel. However, it is important to keep in mind that effective use of the tool requires 
training of health care personnel.
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Introduction
Heart failure (HF) is a global pandemic currently affect-
ing at least 26 million people worldwide. Its prevalence 
is growing as the population ages and other risk factors 
increase [1]. Despite optimal recommended therapies, 
and apart from uncontrolled disease-related symptoms 
such as shortness of breath, pain, sleep disorders, and 
fatigue [2], people living with HF often suffer from other 
conditions such as depression and anxiety [3]. Moreo-
ver, taking care of or living with a person suffering from 
chronic HF can be stressful and burdensome [4]. Both 
patients with HF and their families are at increased risk 
of experiencing physical, emotional, and financial bur-
dens that may impair their quality of life [5]. Failure to 
assess such burdens routinely and systematically in daily 




†Steffen Eychmüller and Maud Maessen have contributed equally.
1 Institute of Social and Preventive Medicine (ISPM), University of Bern, 
Bern, Switzerland
Full list of author information is available at the end of the article
Page 2 of 11Gonzalez‑Jaramillo et al. Health Qual Life Outcomes          (2021) 19:214 
Needs assessment tools are clinical decision aids, facili-
tating the detection of patient needs and the assignment 
of actions to address them according to the available 
care options. These tools used as a support and a start-
ing point for delivering patient-centered care [6]. Two 
recent systematic reviews found six needs measurement 
tools that can be used with patients with HF [6, 7]. Both 
systematic reviews found that the most comprehensive 
of these tools and the only one created specifically for 
patients with HF is the “Needs Assessment Tool: Pro-
gressive Disease-Heart Failure” (NAT: PD-HF) [8].
The NAT: PD-HF was developed in 2013 by Austral-
ian researchers to help health care personnel identify 
the needs of patients with HF and their informal caregiv-
ers, and match them with the most appropriate services 
regardless of whether they may be psychology, social 
work, cardiology, specialized palliative care, or general 
medicine [8]. The NAT: PD-HF, more than a question-
naire, is a direct, face-to-face interaction guide aimed 
to increase the attention dedicated to patients and their 
narratives in a highly efficient and effective way. Clinical 
environments that optimize this attention, will not only 
improve the quality of care and patient and staff satisfac-
tion, but also reduce care costs [9, 10]. The implementa-
tion of the NAT: PD-HF in the clinical practice could be 
a fundamental basis for strategies focusing on optimizing 
attention.
To date the NAT: PD-HF has been available in only 
English [8] and Dutch [11]. We therefore (1) trans-
lated the tool into German and culturally adapted it, (2) 
assessed psychometric characteristics of the translated 
NAT: PD-HF that include internal consistency, inter-
rater reliability, and test–retest reliability, (3) evaluated 
whether and how patients and health care personnel 
understood the tool and its utility, and (4) assessed the 
face validity, applicability, relevance, and acceptability of 
the German NAT: PD-HF among health care personnel.
Methods
Study design
We conducted this work at Inselspital, the University 
Hospital of Bern, Switzerland, a tertiary academic hospi-
tal with a dedicated HF clinic and a specialized palliative 
care service. Translation and validation of the original 
tool was performed in accordance with the guidelines 
of the European Organisation for Research and Treat-
ment of Cancer [12]. We performed separate forward and 
backward translations (Additional file  1), and evaluated 
internal consistency, inter-rater reliability, and test–retest 
reliability.
We surveyed patients (Additional file  2) and health 
care personnel (Additional file 3) to gauge their level of 
understanding of the NAT: PD-HF and perception of its 
utility. Face validity, applicability, relevance, and accept-
ability of the tool by health care personnel were assessed 
with interviews of personnel specializing in cardiology 
and palliative care (PC) at our institution (Additional 
file 4). Sociodemographic and basic clinical information 
of the participants was extracted from electronic medical 
records.
The original NAT: PD‑HF tool
The NAT: PD-HF is a comprehensive tool designed for 
health care personnel to assess both a patient’s and a 
main informal caregiver’s physical, psychological, social, 
and spiritual needs [8]. It consists of three parts: the first 
one is a user guide explaining the purpose of the tool and 
how to complete it, the second is a questionnaire com-
prised of 20 items, and the third section has examples 
of what to address within each item of the questionnaire 
(Additional file  5). The questionnaire is subdivided into 
sections addressing four topics: (1) priority referral for 
further assessment, (2) patient well-being, (3) ability of 
the informal caregiver or family to care for the patient, 
and (4) caregiver well-being. For each question, health 
care personnel selects the level of concern together with 
the patient: (1) none, (2) some/potential, (3) significant. 
If there is some/potential or significant concern in one of 
the questions, the patient has unmet needs. The health 
care worker proceeds to choose an appropriate action: 
(1) directly manage it, (2) management by another care 
team member, or (3) refer. If the last option is chosen, 
the yellow box at the end of the questionnaire (under the 
heading: referral required for further assessment of care) 
should be filled in. In this section, there is the option to 
refer to other providers such as the patient’s general prac-
titioner, social worker, psychologist, specialist PC service, 
cardiologist, or other.
Translation and cultural adaptation
The NAT: PD-HF was translated from English to German 
using a forward–backward translation procedure and 
cultural adaptation by four translators, one of which was 
a professional medical text translator (Additional file 1). 
Cultural adaptation required minimal change to the third 
part of the NAT: PD-HF, which includes examples of 
what to address within each of the questionnaire items 
(Additional file 6). The second part of the NAT: PD-HF, 
the questionnaire itself, did not require any cultural 
adaptation. Therefore, we did not consider it necessary to 
validate the content of the culturally adapted version.
After pilot testing the translated tool with 19 patients, 
we made small adjustments to the translation, and in 
the recruitment process. The pilot test also revealed 
the need to train health care personnel who will use the 
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tool. Because of the adjustments after the pilot test, we 
excluded pilot participants from the final analysis.
Participants and recruitment
Eligible participants were adult patients (≥ 18  years of 
age) with an appointment at the Heart Failure Clinic 
at Inselspital Bern who had had at least one consulta-
tion in the clinic and who could fluently communicate 
in German. No specific stage or severity of HF was 
selected to ensure a representative, full spectrum of the 
disease.
Patients meeting the inclusion criteria received a 
study invitation package containing an invitation letter 
and study description, a participant information sheet 
and consent form, and a removable response card that 
patients could send back to the research team stating 
whether they were interested in taking part of the study 
or not. For those who were interested, we arranged an 
appointment with a study member immediately before 
or after their scheduled consultation at the HF clinic.
We evaluated patients’ cognitive capacity by ask-
ing them three questions about the study after having 
explained its purpose and the content from the con-
sent form. The questions were (1) what is the aim of 
the study? (2) In which patients will the study be per-
formed? (3) As part of this study, will you have blood 
tests or ultrasounds? In case of satisfactory answers to 
the three questions, the interviewer proceeded with the 
signing of the consent form and the interview.
Study procedure
Using the tool with HF patients
Using the German version of the NAT: PD-HF a general 
practitioner trained in administering the tool directly 
queried the patient and, if present, an informal car-
egiver. From these data we estimated internal consistency 
(Fig.  1). The encounter was recorded to allow a second 
evaluator to provide data for gauging inter-rater reliabil-
ity using the audio recording (Fig. 1). After 10 to 20 days, 
a second appointment was scheduled with the patient 
and the NAT: PD-HF was repeated face-to-face by the 
same evaluator who used the tool during the first assess-
ment to provide data for gauging test–retest reliability 
(Fig. 1).
Assessing understanding of the German NAT: PD‑HF and its 
utility
At the end of the study, we asked patients to tell us 
whether they thought the NAT: PD-HF questions were 
easy to understand and answer, and whether the ques-
tions might lead to better care. We obtained their answers 
via a five-point Likert scale ranging from ’’strongly agree’’ 
to ’’strongly disagree’’ (Additional file  2). We also asked 
about whether such questions are addressed in the course 
of their regular clinical consultations, and asked them 
what other questions they thought should be included in 
the tool.
We asked health care personnel representing all poten-
tial patient referral services to complete the same survey 
that patients completed (Additional file 3).
Fig. 1 Study procedure. Adobe Illustrator Draw was used to create the artwork
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Face validity, applicability, relevance and acceptability
Interviews were conducted with the group of health care 
personnel to assess face validity, applicability, relevance, 
and acceptability of the German NAT: PD-HF (Addi-
tional file 4).
Data analysis
Internal consistency and sample size
We used Cronbach’s alpha to assess internal consistency. 
Sample size calculations were based on Feldt´s formula 
[13]. To have 80% power at an alpha error of 5%, a low-
est acceptable Cronbach´s alpha value of 0.75, and an 
expected value of 0.85, the sample size calculated was 66. 
Estimating a dropout rate of 10% we aimed to recruit 75 
patients.
Inter‑rater reliability and test–retest reliability
To assess the agreement between the results obtained 
from the physician using the NAT: PD-HF the first time 
and the results when the second evaluator filled out the 
tool listening the recordings, it is the inter-rater reliabil-
ity, we used Cohen`s kappa. Since our data were ordinal, 
we used Cohen’s weighted kappa. According to Cohen, 
1968, the investigators choose the weights based on 
their own judgment [14]. Weights should be defined so 
that a weight of 1 (a full weight) is assigned to diagonal 
agreements, whereas decreasing weights are assigned 
to partial agreements depending on the problem under 
investigation [15]. We defined weight in such a way 
that the difference between “No concern” and “Some/
potential concern” is less than the difference between 
“No concern” and “Significant concern.” We similarly 
regarded the difference between “No concern” and 
“Some/potential concern” as greater than the difference 
between “Some/potential concern” and “Significant con-
cern” since, in the second case, at least, the profession-
als agreed that some additional action should be taken. 
(The NAT: PD-HF instructions state that the professional 
using the tool should act on each identified need). We 
weighted the agreement of the two evaluators acknowl-
edging these differences as presented in Additional file 7: 
Table 1.
The frequency of some/potential and significant con-
cerns were low for some of the NAT: PD-HF items 
(Additional file 8: Table 2). We therefore decided to addi-
tionally report the results of the prevalence-adjusted and 
bias-adjusted kappa (PABAK) to avoid obtaining inflated 
agreements due to bias introduced by those low frequen-
cies [16].
To assess the agreement between the results of the 
physician using the tool the first time and the results of 
the same physician using the tool the second time, it is 
the test–retest reliability, we estimated Cohen`s. For this 
calculation, we used the same weights presented in the 
Additional file 7: Table 1, as well as PABAK.
We interpreted inter-rater and test–retest reliabilities 
as near-perfect agreement if the kappa was greater than 
0.81, as substantial if the kappa was between 0.61 and 
0.80, moderate if it was between 0.41 and 0.60, and poor 
if it was less than 0.40 [17].
Unlike the first evaluator, the second evaluator was not 
always the same. Therefore, we did a sensitivity analysis 
to assess the inter-rater reliability for each one of the two 
second evaluators and define whether the data could be 
analyzed as a whole or if we needed to account for sec-
ond evaluator differences.
Survey of patients and health care personnel
To summarize surveys results, “Strongly agree” and 
“Agree,” were pooled with each other and “Disagree” and 
“Strongly disagree” were pooled with each other. The 
original five-point Likert scale was thus converted into a 
three-point scale for the analysis. All analyses were per-




Between December 2019 and March 2020, 200 patients 
meeting the inclusion criteria were invited to participate. 
Among those invited, 70 patients consented to partici-
pate, giving a recruitment rate of 35% (Fig.  2). Though 
men predominated among the invitees, women (12/30, 
40%) were slightly more willing to participate than men 
(58/170, 34%) (Fig. 2). There was no loss to follow-up.
A large majority of the patients included in the study 
were men (58/70, 83%); the mean age of all participants 
was 62.0  years (SD 13.7) (Table  1). The majority of the 
patients (45/70, 64%) had a reduced (≤ 40%) left ventric-
ular ejection fraction (LVEF). Among the remaining 25 
patients, three had a borderline (41–49%) LVEF, and the 
LVEF was preserved (≥ 50%) in 22. Half of the patients 
were classified as NYHA II, while none was classified as 
NYHA IV.
The interviews took an average of 24.1  min (SD 9.7) 
and the frequency of answers for each question is pre-
sented in Additional file 8: Table 2. Almost all the patients 
(67/70) reported the availability of an informal caregiver 
in case of need, the majority of whom are their partners 
(49/67, 73%). Patients were also asked about their need 
for more information about the course and prognosis of 
the disease and about treatment. Twenty-six reported a 
need for more information about one or more of seven 
aspects of living with HF; the largest need reported was 
that for information on legal and financial issues (Addi-
tional file 8: Table 2).
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Tool translation
The culturally adapted German translation of the NAT: 
PD-HF is presented in Additional file 1.
Psychometric characteristics of the German NAT: PD‑HF
Internal consistency
With a Cronbach’s alpha of 0.83, the internal consistency 
was high. Furthermore, when removing each question to 
evaluate how the alpha changed without each item Cron-
bach’s alpha ranged from 0.80 and 0.84. Details of the 
psychometric characteristics are presented in Table 2.
Inter‑rater reliability
Overall, based on Cohen´s kappa 13 out of the 14 ques-
tions reached at least moderate agreement (defined as 
a kappa value ≥ 0.41). Three questions about patient´s 
wellbeing in section "2" had an almost perfect, three had 
substantial and only one had poor agreement. This last 
question, that is the last one of the section, aims to iden-
tify the health beliefs of patients and cultural or social 
factors that might be barriers to health delivery. Among 
the six questions assessing the ability of the caregiver to 
take care of the patient in section  "3", three questions 
were in almost perfect agreement, two had substantial 
agreement, and the remaining one moderate agreement. 
The question from section "4" about the caregiver´s well-
being had substantial agreement (Table 2).
We observed no differences in the performance of the 
different first and second evaluators (Additional file  9: 
Table 3). Therefore, there was no need to account for sec-
ond evaluators’ differences in the analyses.
Test–retest reliability
The median time between the two appointments was 
15  days (IQR 14–20) and none of the patients reported 
any significant change in his or her condition between 
the two appointments. Test–retest reliability of the Ger-
man NAT: PD-HF was very high and all questions had 
almost perfect agreement, with Cohen`s kappa ranging 
from 0.82 to 1.00 (Table 2).
Survey of patients
All of the 70 participants agreed that the tool ques-
tions were easy to understand and answer. Sixty-one 
patients (87%) thought that discussing the issues raised 
in the questions may improve quality of care. Only three 
Fig. 2 Flowchart of the participants included in the study
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patients reported these questions being routinely asked 
or discussed during clinical consultations (Table 3).
Regarding other questions that should be included in 
the tool, the most frequently mentioned topics were life-
style habits and sexuality. More specifically, patients sug-
gested inquiry about exercise and nutrition habits, and 
whether there have been changes in a couple’s sex life and 
there are side effects of medication that interfere with it.
Survey of health care personnel
We interviewed 27 health care professionals. These 
included eight cardiologists, five cardiology nurses, four 
PC specialists, three PC nurses, three psychologists from 
the HF clinic, two general practitioners, and two social 
workers. Among the 27 interviewees, 21 were women, 
and 14 of the interviewees have worked in the profession 
for more than 10 years.
In general, the health care personnel rated the ques-
tions easy for patients to understand, but not to answer. 
Most (23 of the 27 professionals) considered the tool 
helpful for improving the quality of patient care. Eleven 
of the health care personnel reported that the questions 
in the tool are usually asked during a clinical consul-
tation, while the remaining 16 responded in a neutral 
manner, neither agreeing nor disagreeing. The four PC 
specialists agreed that topics from the tool are discussed 
during a routine consultation with a PC specialist. In 
contrast to that, only two of the cardiologists said top-
ics from the tool are discussed in consultations, while the 
remaining six said that most “are not addressed,” and that 
“psychosocial aspects are not discussed” (Table 3).
Face validity, applicability, relevance and acceptability
Face validity
Face validity was rated high, with most of the health care 
personnel (23 of 27) agreeing that the tool appears to 
measure unmet needs of both patients with HF and their 
caregivers. The remaining four interviewees partially 
agreed, but thought that to properly assess caregiver 
needs the caregiver needs to be present in the interview 
(Table 4).
Applicability
Among the 27 health care personnel, 17 (63%) consider 
the tool easy to use, and all but two consider the writ-
ten instructions on use the tool helpful. However, some 
thought the tool and its instructions were too long and 
too detailed.
PC specialists, psychologists, and social workers think 
that doctors (general practitioners, cardiologists, PC spe-
cialists) as well as nurses can use the tool, while cardiol-
ogy staff think that mainly nurses should use it (Table 4).
Relevance
Two PC specialists, one general practitioner and a psy-
chologist, each questioned the relevance of some ele-
ments of the tool. One of the PC specialist was not sure 
what question 2.5 should cover. The other PC specialist 
said that question 2.7 is not very useful since it collapses 
Table 1 General characteristics of the population included in 
the study
IQR interquartile rate, LVEF left ventricular ejection fraction, HFrEF heart failure 
with reduced ejection fraction, HFmrEF heart failure with mildly reduced ejection 
fraction, HFpEF heart failure with preserved ejection fraction, ICD implantable 
cardioverter defibrillator, VAD ventricular assist device, COPD chronic obstructive 
pulmonary disease, CAD coronary artery disease, CKD chronic kidney disease

















LVEF (%) 35 (20–50)











Presence of caregiver 67 (95%)
Caregiver
Couple 49 (73%)




Have requested referral to palliative care 0 (0.0%)
Have an advance directive 25 (36%)
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different factors into a single question, and suggested 
that section three, which is about the ability of caregiver 
to care for the patient, and section four, about caregiver 
well-being, should be merged. The GP thought question 
3.6 is not very clear and should be rephrased, and the 
psychologist thought that questions 2.3 and 2.5 have sim-
ilar content (Table 4).
Acceptability
There was no consensus on either when or how often the 
NAT: PD-HF should be employed in clinical practice. 
Some believe that it should be used early, at the first or 
second consultation, while others believe that it is better 
not to use it early, but only after a basis of trust has been 
built with the interviewer and the patient has already 
Table 2 Inter‑rater and test–retest reliability
PABAK prevalence‑adjusted and bias‑adjusted kappa
Inter‑rater reliability Test–retest reliability
Cohen´s kappa PABAK Cohen´s kappa PABAK
Section 2: Patient wellbeing
1. Is the patient experiencing unresolved physical symptoms (including problems with breath‑
lessness, pain, fatigue, nausea, edema, insomnia, or cough)?
0.43 0.49 0.94 0.94
2. Does the patient have problems with daily living activities? 0.59 0.79 0.99 0.98
3. Does the patient have psychological symptoms that are interfering with well‑being or rela‑
tionships?
0.69 0.76 0.94 0.94
4. Does the patient have concerns about how to manage his/her medication and treatment 
regimens?
0.48 0.94 1.00 1.00
5. Does the patient have concerns about spiritual or existential issues? 0.88 0.96 0.90 0.97
6. Does the patient have financial or legal concerns that are causing distress or require assis‑
tance?
0.85 0.89 0.93 0.94
7. From the health delivery point of view, are there health beliefs, cultural, or social factors involv‑
ing the patient or family that are making care more complex?
0.17 0.80 0.90 0.97
Section 3: Ability of caregiver or family to care for patient
1. Is the caregiver or family distressed about the patient’s physical symptoms? 0.83 0.98 0.83 0.98
2. Is the caregiver or family having difficulty providing physical care? 0.78 0.84 0.82 0.87
3. Is the caregiver or family having difficulty coping? 0.82 0.88 0.97 0.98
4. Is the caregiver having difficulty managing the patient’s medication and treatment regimens? 1.00 1.00 1.00 1.00
5. Does the caregiver or family have financial or legal concerns that are causing distress or 
require assistance?
0.66 0.87 1.00 1.00
6. Is the family currently experiencing problems that are interfering with their functioning or 
interpersonal relationships or is there a history of such problems?
0.57 0.79 0.96 0.97
Section 4: Caregiver wellbeing
1. Is the caregiver or family experiencing physical, practical, spiritual, existential, or psychological 
problems that are interfering with their well‑being or functioning?
0.73 0.89 0.85 0.93
Table 3 Results of the survey applied to patients and health care personnel
Agree Neither agree 
nor disagree
Disagree
Survey to patients (n = 70)
1.The questions were, generally, easy to understand (n = 69) 69 (100%)
2.The questions were, generally, easy to answer (n = 69) 69 (100%)
3.If my doctor asks me these questions, it may help to improve the quality of my care (n = 68) 61 (90%) 6 (9%) 1 (1%)
4.The questions asked in the questionnaire are usually dealt with during the clinical consultation (n = 70) 3 (4%) 38 (54%) 29 (42%)
Survey to health care personnel (n = 27)
1.In general, the questions were easy to understand for the patient (n = 27) 13 (48%) 14 (52%)
2.In general, the questions were easy to answer for the patient (n = 27) 10 (37%) 16 (59%) 1 (4%)
3.The quality of the care is improved by applying this tool (n = 27) 23 (85%) 4 (15%)
4.The questions asked in the questionnaire are usually dealt with during the clinical consultation (n = 25) 11 (44%) 14 (56%)
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Table 4 Results of the interview to assess tool´s face validity, applicability, relevance and acceptability among health care personnel
Agree Neutral Disagree Comments to highlight
Face validity (n = 27)
1) The tool measures unmet needs of patients with heart 
failure and their caregivers
23 (85%) 4 (15%) “to properly assess caregiver needs, the caregiver should 
be present in the interview”, “the tool is more useful for 
younger patients as they may have a higher disease bur‑
den than older patients”
Applicability (n = 27)
1) The tool is easy to use 17 (63%) 7 (26%) 3 (11%) “very complex and detailed”, “difficult to differentiate 
between Some/Potential and Significant in the level of 
concern”
2) Different professional groups can fill out the tool 23 (85%) 4 (15%)
2. a) Which professional group should fill out the tool? Palliative care staff (nurses and physicians) replied: physi‑
cians and nurses;
General practitioners and social workers replied: physi‑
cians, nurses, social worker; Psychologists replied: physi‑
cians and nurses
Cardiology staff (nurses and physicians) replied: mainly 
nurses;
3) The tool instructions are was easy to understand 27 (100%)
4) The tool instructions are helpful 25 (93%) 2 (7%) "instructions are useful but too long"
5) A special training is necessary to fill out the tool 16 (59%) 1 (4%) 10 (37%) "for certain items, explanations are required", "maybe not a 
training, but an introduction to explain the purpose of the 
tool to increase motivation", "online training is an option", 
"training is required for non‑specialized nurses", "the first 
and the last page of the tool have a lot of information that 
can be explained during a training session"
6) There are some difficulties in using the tool 18 (67%) 4 (15%) 5 (18%) "many questions involve several aspects", "regarding the 
field action taken, there are situations you cannot act", 
"patients’ needs sufficient linguistic and cognitive skills", 
"an entire clinic needs to be willing to use the tool", " time 
consuming, especially with patients who have a lot to say", 
"needs a lot of time and empathy", "if filled out by nurses, 
they are not allowed to refer patients"
Relevance (n = 27)
2) Some questions are irrelevant and can be left out 1 (4%) 3 (11%) 23 (85%) "3.6: it is not clear what the question intends to assess", 
"2.7: not very useful", "2.7: formulated very complicated 
and too long", “section 3" and "4" are repeated and should 
be merged”, “questions 2.5 and 2.3 have a similar content”, 
"2.5: not sure what it should capture"
Acceptability (n = 27)
1) Filling out the tool does not take too much time and 
can be integrated into daily routine clinical practice
13 (48%) 5 (19%) 9 (33%) "it is too long and takes too much time", "it requires train‑
ing or a very complete introduction", "not possible in the 
cardiology consultation, maybe the palliative care has 
time"
a) When should the tool be applied? "early, in the first or second consultation", "not too early, 
it needs a basis of trust", "not too early, when the patient 
has dealt with the disease", "if the patient becomes more 
symptomatic or consultations become more frequent"
b) How often should the tool be applied? "when something has change", "at rehospitalisation", 
"regularly, every 6 months", "during annual controls", 
"in patients who are deteriorating faster", "after regular 
intervals of 6 ‑12 months ask those questions where there 
were needs", "ask in every consultation if something has 
changed"
2) I feel uncomfortable asking some of the questions 4 (15%) 9 (33%) 14 (52%) "questions 2.3, 2.5, 2.6, 3.6 and 4.2 are about topics hard to 
discuss (emotional, spiritual concerns, family or financial 
issues)", "patient may not like to talk about financial issues 
(question 2.6)", "2.5 and 2.6 need to be asked carefully 
(spiritual concerns or financial issues)", "2.3 is very personal 
(psychological issues)"
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dealt with the disease. Some respondents think it should 
be used at regular intervals such as every six months or 
at annual check-ups, while others think it should be used 
again after major changes in health status or after hospi-
talization (Table 4).
The main concerns about accepting the NAT: PD-HF 
are lack of time to use it, and that being able to use it 
requires some training or at least a very thorough intro-
duction to using it and its value (Table 4).
Another reservation about using the NAT: PD-HF 
reported by cardiologists and cardiology nurses was that 
some staff members do not feel comfortable discussing 




We translated the NAT: PD-HF into German, culturally 
adapted, and validated it. The validation showed good 
internal consistency and substantial inter-rater agree-
ment for the majority of the items. Additionally, we were 
able to assess the test–retest reliability and we found 
almost perfect agreement between the first and second 
assessments. Moreover, patients thought well of the tool, 
and they agreed that it could help to improve their qual-
ity of care and that it covered relevant topics that are not 
normally addressed in clinical consultations. Similarly, 
face validity and user-friendliness were rated highly by 
health care professionals. However, like the participating 
health care personnel we also believe training is neces-
sary to ensure correct use of the tool.
NAT: PD‑HF strengths
Other such tools based on patient prognosis ignore the 
needs that patients with longer prognoses may have, and 
how difficult it is to predict disease trajectory in HF [18–
20]. The NAT: PD-HF evaluates patient needs in a more 
integrated and profound way. It assesses not only patient 
well-being and information needs, but also the needs 
and well-being of family members and informal caregiv-
ers. Two recently published systematic reviews of tools 
to assess PC needs in patients with HF concluded that 
the NAT: PD-HF was the most appropriate tool to assess 
the needs of patients with HF [6, 7]. The English version 
of the tool had already demonstrated a good correlation 
between evaluators [8] and good acceptability by health 
professionals [8, 11]. Our study supports the previous 
findings and additionally shows that the NAT: PD-HF is 
stable over time and that patients regard it as useful.
NAT: PD‑HF limitations
We observed no consensus across medical staff on when 
to use the tool for the first time, nor on how often to use 
it. However, a recently published position statement from 
the European Association of Palliative Care proposed 
an algorithm for when to employ the NAT: PD-HF. The 
association also recommended assessing PC needs in 
patients in less advanced stages of HF at annual reviews 
or after any significant health-related event for those in 
more advanced stages [21].
Although the tool was designed to be used without 
training, experience with the staff in this study showed 
that prior training is necessary. Training was mainly on 
how to discuss the needs of the patients and the infor-
mal caregiver in an empathic, respectful and efficient way 
by applying situation-specific adaptations of the example 
sentences of the instruction manual and on how to decide 
on cut-off points of the scoring system. In a similar study 
assessing the NAT: PD-HF in the Netherlands, nurses 
trained in using the tool still requested they referred that 
more training to assess PC needs [11]. A qualitative study 
that evaluated barriers in the implementation of the 
Needs Assessment Tool: Progressive Disease-Interstitial 
Lung Disease (NAT: PD-ILD), also found the need for 
training for the correct application of that tool [22].
The majority of the questions had a substantial inter-
rater agreement. In section  "2", question number seven 
had a Cohen´s kappa of 0.17, which is a poor correla-
tion. This finding is consistent with the validation of the 
English version of the NAT: PD-HF and the NAT: PD-
Cancer [8, 23]. The poor correlation might be the result 
of aiming to assess multiple factors in one question. The 
question, aiming to identify barriers for the health care 
delivery, tries to assess social factors, health beliefs, and 
cultural beliefs from both the patient and the family. One 
rater may focus more on one factor than on others, lead-
ing to obtaining different answers from patients. In sec-
tion "3", question number six had the lowest kappa of the 
section. The difficulties discussing delicate topics such as 
interpersonal problems in the family might explain the 
low kappa. Additionally, this question also aims to assess 
multiple issues within the same question.
Implications for future research
Its high face validity suggests that the translated tool 
appears to measure unmet needs of patients with HF 
and their informal caregivers, and both medical staff and 
patients think the tool could help to improve quality of 
care. However, its effectiveness in reducing unmet needs 
and consequently even improving quality of life has not 
yet been studied. It would be interesting to prospectively 
study the effectiveness of this tool in reducing unmet 
needs and increasing quality of life in clinical practice.
Additionally, this study aimed to assess the psychomet-
ric characteristics of the German NAT: PD-HF in a rep-
resentative full-spectrum of HF patients. However, the 
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psychometric profile of the tool might differ according 
to characteristics such as NYHA functional class, patient 
gender, or the availability of a caregiver. A study assessing 
these differences should take into account the sample size 
needed to make such subgroup analyses.
Implications for clinical practice
Although we tried to include patients from across the 
disease spectrum, most patients were male and had 
reduced ejection fraction. Patients with preserved ejec-
tion fraction are more often women, are older, and have 
more comorbidities (and therefore more symptoms) such 
as diabetes, hypertension, and renal dysfunction [24, 25]. 
In addition, drugs that have shown to improve symptoms 
in patients with reduced ejection fraction have shown lit-
tle or no effectiveness in patients with preserved ejection 
fraction [26]. Therefore, the latter patients might have 
different types of needs than patients with reduced ejec-
tion fraction. However, this study did not seek to assess 
the needs in patients with HF but rather to evaluate 
the psychometric characteristics of the tool. Hence, we 
believe that the low proportion of patients with preserved 
ejection fraction and women does not limit the general-
izability of our results to clinical practice. However, we 
acknowledge that, due to the low proportion of women 
in our study (17%), we do not know the acceptability and 
women´s opinion of the German NAT: PD-HF. Similarly, 
due to the lack of participation of patients at NYHA IV, 
we do not know their acceptance of the tool, which could 
be low due to the cognitive challenge that answering this 
questionnaire could pose for these patients.
More than one-third of the patients cited a need for 
further information. During interviews some staff also 
mentioned that they did not feel comfortable discuss-
ing certain topics. These reports from patients and staff 
together suggest that improving doctor-patient commu-
nication may assist using the NAT: PD-HF more effec-
tively in clinical practice to recognize unmet needs and 
improve daily life for people living with HF. As attention 
is linked to higher-quality communication, one way to 
improve communication would be to adjust the condi-
tions of clinical practice so that patients and their narra-
tives receive sufficient attention for the physician to fully 
understand their situation or need [9].
Conclusion
The German NAT: PD-HF is a reliable, valid, and inter-
nally consistent tool that is well accepted by both patients 
and health care personnel. However, it is important to 
keep in mind that effective use of the tool requires train-
ing of health care personnel.
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